Introduction
The 8th annual Multiple Sclerosis Nurses at the Limits (MSNATL) meeting takes place in London on Friday 14 & Saturday 15 November 2025. Once again, the chairs have selected a range of topics and speakers which are directly relevant to the challenges facing MS Nurses today, and as well as an outstanding programme there will be plenty of time for discussion, debate and networking with colleagues from around the UK. Register now to attend the fastest growing MS Nurses event in the UK.
Accreditation
Accreditation will be applied for.
Audience
Multiple sclerosis specialist and senior nurses.
Registration fee
Registration is free for HCPs and includes access to all medical sessions.
Funders
Multiple Sclerosis Nurses at the Limits is supported by way of grants or sponsorship from the pharmaceutical industry. Our supporters have no involvement in the organisation of this event, or the selection of speakers or topics which are handled entirely independently by the event Chairs. Supporters are invited to send a delegation of senior company representatives to attend, and their role is simply to continue building the crucial understanding between academia and industry in a scientific setting. Full disclosure of contacted supporters will appear on the event website and be available at the venue during the event.
Funders will host pharmaceutical industry promotional satellite symposia. The sessions are clearly marked on the agenda and will be introduced on-site
Chairs
With a deep understanding of the challenges facing MS Nurses, the chairs bring a wealth of experience to the task of leading the event. In creating the meeting, they have drawn upon their personal awareness of the disease area, the ongoing knowledge shared by colleagues and the feedback from previous gatherings to ensure that the meeting is highly relevant and enjoyable for the Nurse community.
The Lancet
This meeting is endorsed and supported by the Lancet, The Lancet Neurology and eClinicalMedicine.
Contact us
If you require any assistance, please contact us
Follow us:
